Skip to main content

Table 2 Associations between GAS6 and all-cause death or cardiovascular death, with adjustment for clinical characteristic

From: Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial

 

95% CI

P value

c-index

All-cause death

 Model 1

1.65 (1.41,1.93)

< 0.001

0.70 (0.66,0.74)

 Model 2

1.56 (1.33,1.83)

< 0.001

0.79 (0.76,0.83)

 Model 3

1.44 (1.22,1.70)

< 0.001

0.81 (0.78,0.85)

Cardiovascular death

 Model 1

1.71 (1.40,2.09)

< 0.001

0.68 (0.63,0.73)

 Model 2

1.60 (1.30,1.95)

< 0.001

0.81 (0.77,0.85)

 Model 3

1.44 (1.17,1.79)

0.001

0.83 (0.80,0.87)

  1. Standardized hazard ratios, reflecting the instantaneous risk of the primary and secondary endpoint per one standard deviation increase in the ln-transformed biomarker level
  2. Model 1: age, sex, GAS6;
  3. Model 2: age, sex, BMI, smoking, hypertension, diabetes, atrial fibrillation, eGFR, diuretics, Spironolactone, GAS6;
  4. Model 3: age, sex, BMI, smoking, hypertension, diabetes, atrial fibrillation, eGFR, diuretics, spironolactone, GAS6, NT-proBNP, TnT, CRP
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us